Ashish Saxena

4.0k total citations · 2 hit papers
89 papers, 2.6k citations indexed

About

Ashish Saxena is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ashish Saxena has authored 89 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Ashish Saxena's work include Lung Cancer Treatments and Mutations (13 papers), Helicobacter pylori-related gastroenterology studies (13 papers) and Aldose Reductase and Taurine (12 papers). Ashish Saxena is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Helicobacter pylori-related gastroenterology studies (13 papers) and Aldose Reductase and Taurine (12 papers). Ashish Saxena collaborates with scholars based in United States, India and Sweden. Ashish Saxena's co-authors include Jeffrey L. Port, Nasser K. Altorki, Brendon M. Stiles, Timothy E. McGraw, Vivek Mittal, Geoffrey J. Markowitz, Dingcheng Gao, Kota V. Ramana, Satish K. Srivastava and Ravinder Tammali and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ashish Saxena

82 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The lung microenvironment: an important regulator of tumour growth and metastasis

2018 795 citations Nasser K. Altorki, Jeffrey L. Port et al. profile →
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

2021 210 citations Nasser K. Altorki, Timothy E. McGraw et al. profile →

Peers

Countries citing papers authored by Ashish Saxena

Since Specialization

Citations

This map shows the geographic impact of Ashish Saxena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish Saxena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish Saxena more than expected).

Fields of papers citing papers by Ashish Saxena

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashish Saxena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish Saxena. The network helps show where Ashish Saxena may publish in the future.

Co-authorship network of co-authors of Ashish Saxena

This figure shows the co-authorship network connecting the top 25 collaborators of Ashish Saxena. A scholar is included among the top collaborators of Ashish Saxena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish Saxena. Ashish Saxena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study	Arthritis Care & Research	Deanna Jannat‐Khah, Fenglong Xie et al.	0
2	Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?	Arthritis & Rheumatology	Deanna Jannat‐Khah, Jeffrey R. Curtis et al.	0
3	“You Always Worry”: Scan-Related Anxiety Among Patients With Metastatic Lung Cancer	Journal of the American College of Radiology	Heather M. Derry, Holly G. Prigerson et al.	0
4	Advancements in small cell lung cancer	Seminars in Cancer Biology	Ashish Saxena et al.	33
5	Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes	Journal of Thrombosis and Haemostasis	Babak B. Navi, Cenai Zhang et al.	22
6	Automated Retinal Vascular Topological Information Extraction From OCTA	2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)	Ashish Saxena, Jacqueline Chua et al.	1
7	Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline	Journal of Clinical Oncology	Megan E. Daly, Nofisat Ismaila et al.	40
8	Extracellular vesicles from human airway basal cells respond to cigarette smoke extract and affect vascular endothelial cells	Scientific Reports	Ashish Saxena, Matthew S. Walters et al.	15
9	Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report	Clinical Lung Cancer	Ashish Saxena, Jeffrey L. Port et al.	16
10	Development of the Oncolo-GIST (“Giving Information Strategically & Transparently”) Intervention Manual for Oncologist Skills Training in Advanced Cancer Prognostic Information Communication	Journal of Pain and Symptom Management	Andrew S. Epstein, Valerie F. Reyna et al.	11
11	P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)	Journal of Thoracic Oncology	Nasser K. Altorki, Alain Borczuk et al.	14
12	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC	Journal of Thoracic Oncology	W. Marston Linehan, Viola W. Zhu et al.	54
13	Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction	Biochemical Pharmacology	Himangshu Sonowal, Pabitra Bikash Pal et al.	29
14	Didymin prevents hyperglycemia-induced human umbilical endothelial cells dysfunction and death	Biochemical Pharmacology	Kirtikar Shukla, Himangshu Sonowal et al.	32
15	Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent	Medical Oncology	Ashish Saxena, Bryan J. Schneider et al.	10
16	Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again	The Oncologist	Ashish Saxena, Daniel Becker et al.	31
17	QUANTIFICATION OF URAPIDIL IN HUMAN PLASMA USING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY–ELECTROSPRAY IONIZATION MASS SPECTROMETRY (UPLC–MS/MS) FOR PHARMACOKINETIC STUDY IN HEALTHY INDIAN VOLUNTEERS	International Journal of Pharmacy and Pharmaceutical Sciences	Ashish Saxena, Arun Kumar Gupta et al.	1
18	Rapid and sensitive method for quantification of gestodene in human plasma as the oxime derivative by liquid chromatography–tandem mass spectrometry (LC–MS/MS) and its application to bioequivalence study	Journal of Chromatography B	Ashish Saxena, Arun Kumar Gupta et al.	7
19	Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression	European Journal of Cancer	Ashish Saxena, Mohammad Shoeb et al.	36
20	Inhibition of aldose reductase prevents colon cancer metastasis	Carcinogenesis	Ravinder Tammali, Aramati B. M. Reddy et al.	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact